Format

Send to

Choose Destination
Ann Vasc Surg. 2016 Feb;31:211-20. doi: 10.1016/j.avsg.2015.08.002. Epub 2015 Nov 17.

Current Status of Clot Removal for Acute Pulmonary Embolism.

Author information

1
South Texas Center for Vascular Care, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX. Electronic address: daviesm@uthscsa.edu.
2
Division of Vascular Diseases and Surgery, Ohio State University, Columbus, OH.

Abstract

Acute pulmonary embolism (PE) continues to carry a high mortality if not recognized early and treated aggressively. Rapid recognition and diagnosis remains the mainstay of all efforts. Risk stratification early is paramount to guide therapy and achieve successful outcomes. Pulmonary emboli can generally be classified as massive, submassive, or stable. Fibrinolysis and/or surgical embolectomy are recommended for the treatment of the patient with massive PE to rescue the patient and restore hemodynamic stability. Current trials support an aggressive approach. In submassive PE, determination of right ventricular (RV) strain by echocardiography and biomarker assessment (troponin and B-type natriuretic peptide) identify patients who can benefit from catheter-directed therapy with the therapeutic intent of achieving a rapid reduction of RV afterload, prevention of impending hemodynamic collapse and prolonged in-hospital and outpatient survival. Current trials have not shown long-term benefit for this approach to date, and thus, this therapy should only be offered to select patients. Stable PE can be treated using both an inpatient and an outpatient approach, based on the available infrastructure. Therapy for PE continues to evolve and stratification of risks and benefits remain the key to implementation of invasive strategies.

PMID:
26597237
DOI:
10.1016/j.avsg.2015.08.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center